Czech Ophthalmologic Society’s Data Collecting System for the Monitoring and Evaluating of the Exsudative Age-Related Macular Degeneration Treatment – the Nation-Wide Project “AMADEUS”
Authors:
L. Dušek 1; Š. Pitrová 2; J. Řehák 3; E. Vlková 4; O. Chrapek 3; D. Klimeš 1; P. Brabec 1; V. Kandrnal 1; Jarkovský J. Za Kolektiv Investigátorů Projektu Amadeus 1
Authors‘ workplace:
Institut biostatistiky a analýz, Masarykova univerzita, Brno, ředitel doc. RNDr. Ladislav Dušek, Ph. D., 2Oční klinika Nové Butovice, Praha 5, přednosta MUDr. Ján Lešták, CSc., MBA, 3Oční klinika FN a LF UP, Olomouc, přednosta doc. MUDr. Jiří Řehák, CSc.,
1
Published in:
Čes. a slov. Oftal., 66, 2010, No. 3, p. 99-109
Overview
The Czech Ophthalmologic Society (member of the Czech Medical Society of Jan Evangelista Purkyně) in collaboration with the Institute of Biostatistics and Analysis of the Masaryk University in Brno established a nation-wide information system for the follow-up of the epidemiology and treatment of the exsudative age-related macular degeneration (ARMD). The project named AMADEUS is a multi-centric, non-invasive, observation prospective study with the aim to improve the patients’ treatment and to unify the criteria for the follow-up of the ARMD in the real clinical practice in the Czech Republic. The basic instrument of the whole project is a clinical register collecting parametric data from 9 specialized centers. Especially the project monitors the photodynamic therapy with Verteporfyrine (Visudyne) and treatment by anti-VEGF agents, or Pegaptanib (Macugen) and Ranibizumab (Lucentis). The project’s protocol is trying to collect representative data about ARMD diagnosis and treatment; during regularly controls, the efficacy and safety of the treatment are followed-up. The data collecting does not influence the treatment strategy or the availability of chosen treatment for the patient. Since October 2008 until the end of the year 2009, the registry collected complex information about more than 1402 newly treated ARMD patients; out of them, in 582 cases the one-year follow-up period was regularly terminated. The available data shows well-considered indication of drugs indications by the doctors; the treated patients fulfill the indications criteria set by the scientific society. According to the data from the registry, in some treating centers the application schedule is not followed-up in some drugs (especially Pegaptanib); there is the possibility to improve the treatment. All the clinical centers participating in the AMADEUS registry will continue in the data collecting, which after a longer period of time will facilitate further treatment optimization and eliminating of the established imperfections. Further information about the project may be found at the web site: www.amadeus.registry.cz.
Key words:
Age-related macular degeneration, clinical data collecting, AMADEUS nation-wide project
Sources
1. Shah A.R., Del Priore L.V.: Progressive visual loss in subfoveal exudation in age-related macular degeneration: a meta-analysis using Lineweaver-Burke plots. Am J Ophthalmol 2007; 143, s.83–9.
2. Wong T., Chakravarthy U., Klein R., et al.: The Natural History and Prognosis of Neovascular Age-Related Macular Degeneration: A Systematic Review of the Literature and Meta-analysis. Ophthalmology, 2008; 115(1), s.116–126.
3. Krzyzanowska M., Pintilie M., Tannock I.: Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA 2003; 290, s. 495–501.
4. Bressler, N.M., Bressler, S. B., Fine, S.L.: Age related macular degeneration. Surv. Ophthalmol., 1988; 32, s. 357–412.
5. West S.K.: Looking forward to 20/20: a focus on the epidemiology of eye diseases. Epidemiol Rev 2000; 22, s. 64–70.
6. Kousal B., Dubská Z.: Věkem podmíněná makulární degenerace – principy a léčba. Postgraduální medicína, 2010; 12 (3), s. 257–264.
7. Maloney S.C., Godeiro K.D., Odashiro A.N., Burnier M.N.: Current and Emerging Concepts in the Management of Neovascular Age-Related Macular Degeneration. Cardiovascular & Hematological Agents in Medicinal Chemistry, 2007; 5, s. 147–154.
8. Robman L., Vu H., Hodge A., Tikellis G., et al: Dietary lutein, zeaxanthin, and fats and the progression of age-related macular degeneration. Can J Ophthalmol. 2007; 42, s. 720–726.
9. Beatty S., van Kuijk F., Chakravarthy U.: Macular Pigment and Age-Related Macular Degeneration: Longitudinal Data and Better Techniques of Measurement Are Needed Investigative Ophthalmology & Visual Science, 2008; 49(3), s. 843–845.
10. Lanchoney D.M., Jaguáre M.G., Fine S.L.: A Model of the Incidence and Consequences of Choroidal Neovascularization Secondary to Age-related Macular Degeneration Comparative Effects of Current Treatment and Potential Prophylaxis on Visual Outcomes in High-Risk Patients. Arch Ophthalmol. 1998; 116, s.1045–1052.
11. Seddon J.M., Reynolds R., Maller J., et al.: Prediction Model for Prevalence and Incidence of Advanced Age-Related Macular Degeneration Based on Genetic, Demographic, and Environmental Variables Investigative Ophthalmology & Visual Science, 2009; 50(5), s. 2044–2053.
12. Korobelnik J.F., Moore N., Blin P., et al.: Estimating the Yearly Number of Eyes with Treatable Neovascular Age-Related Macular Degeneration Using a Direct Standardization Method and a Markov Model. Investigative Ophthalmology & Visual Science, 2006; 47 (10), s. 4270–4276.
13. Mitchell J., Bradley C.: Quality of life in age-related macular degeneration: a review of the literature. Health and Quality of Life Outcomes 2006; 4, s.97,
14. Soubrane G., Creuss A., Lotery A., et al.: Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. Arch Ophthalmol 2007; 125, s. 1249–54.
15. Smiddy W.E.: Economic Implications of Current Age-Related Macular Degeneration Treatments. Ophthalmology 2009; 116, s. 481–487.
16. Fletcher E.C., Lade R.J., Adewoyin T., Chiny N.V.: Computerized Model of Cost-Utility Analysis for Treatment of Age-Related Macular Degeneration. Ophthalmology 2008; 115, s. 2192–2198.
17. Brown M.M., Brown G.C., Brown H., Peet J.: A value – based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology 2008; 115, s. 1039–45.
18. Nadkarni P.M., Brandt C., Frawley S., et al.: Managing attribute – value clinical trials data using the ACT/DB client-server database system. J Am Med Inform Assoc 1998; 5(2), s. 139–151.
19. Nadkarni P.M., Brandt C.M., Marenco L.: WebEAV: automatic metadata-driven generation of web interfaces to entity-attribute-value databases. J Am Med Inform Assoc 2000; 7(4), s. 343–356.
20. Nadkarni P.M., Marenco L.: Easing the transition between attribute-value databases and conventional databases for scientific data. Proc AMIA Symp: 2001; s. 483–487.
21. NICE guidelines on Ranibizumab and pegaptamib for the treatment of wet macular degeneration. Issued: August 2008.
22. Rosenfeld P.J., Brown D.M., Heier J.S., et al. for the MARINA Study Group: Ranibizumab for Neovascular Age-Related Macular Degeneration The New England Journal of Medicine, 2006; 355(14), s. 1419–1431.
23. Querques, G., Azrya, S., Martinelli, D., et al.: Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting. Br J Ophthalmol 2010; 94, s. 292–296.
Labels
OphthalmologyArticle was published in
Czech and Slovak Ophthalmology
2010 Issue 3
Most read in this issue
- Treatment of the Choroidal Neovascular Membrane by Ranibizumab (Lucentis): A Case Report
- Epidemiology of the Age-Related Macular Degeneration
- The Change of the anti-VEGF Agent in the Treatment of Exceptionally Active Choroidal Neovascular Membrane in Age-Related Macular Degeneration
- Combined Therapy in the Exsudative Age-Related Macular Degeneration (Photodynamic Therapy and Intravitreally-Applied Ranibizumab)